12 Month Price Forecast For ICCM
Distance to ICCM Price Forecasts
ICCM Price Momentum
๐ค Considering IceCure (ICCM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 3:32 AM UTC
ICCM Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, ICCM has a bullish consensus with a median price target of $3.00 (ranging from $2.50 to $4.60). Currently trading at $1.36, the median forecast implies a 120.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 83.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICCM Analyst Consensus
ICCM Price Target Range
Latest ICCM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICCM.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 27, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
Nov 8, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
Sep 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
Aug 21, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.50 |
Jul 2, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Jun 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
May 29, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Apr 16, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Apr 4, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Mar 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Mar 20, 2024 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $2.90 |
Mar 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Nov 29, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Sep 6, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Aug 15, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $4.00 |
Aug 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Jul 25, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Jun 1, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
May 23, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Mar 28, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
Stocks Similar to IceCure Medical Ltd
The following stocks are similar to IceCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IceCure Medical Ltd (ICCM) Financial Data
IceCure Medical Ltd has a market capitalization of $77.50M with a P/E ratio of -4.3x. The company generates $3.34M in trailing twelve-month revenue with a 40.3% profit margin.
Revenue growth is +7.9% quarter-over-quarter, while maintaining an operating margin of -319.3% and return on equity of -94.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

IceCure Medical Ltd (ICCM) Company Overview
About IceCure Medical Ltd
Develops cryoablation systems for tumor treatment.
IceCure Medical Ltd generates revenue through the sale of its proprietary cryoablation systems and associated disposable products. Their offerings include various systems tailored for different medical specialties, allowing them to cater to a broad market including oncology and urology.
Founded in 2006 and based in Caesarea, Israel, IceCure is positioned within the growing medical device sector, focusing on innovative technologies for tumor ablation. Their diverse product range, including the ProSense and IceSense3 systems, enhances their market potential across multiple healthcare fields.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
71
CEO
Mr. Eyal Shamir
Country
Israel
IPO Year
2011
Website
www.icecure-medical.comIceCure Medical Ltd (ICCM) Latest News & Analysis
IceCure Medical Ltd. presented two studies on ProSenseยฎ cryoablation for breast cancer, winning an award. FDA decision on market authorization expected in Q1 2025.
Positive study results and FDA market authorization expectations for ProSenseยฎ could boost IceCure Medical's stock value and market position in breast cancer treatment.
IceCure Medical has filed for regulatory approval of its ProSenseยฎ Cryoablation System in China, where its IceSense3 system is already approved.
Approval in China could significantly boost IceCure Medical's market potential and revenues, enhancing investor confidence and possibly increasing stock value.
ProSenseยฎ sales rise, indicating increased adoption of its cryoablation for breast tumors. FDA market authorization decision for early-stage breast cancer expected Q1 2025.
Rising ProSenseยฎ sales indicate strong market demand and potential growth. FDA approval in early 2025 could significantly enhance revenue and market position, impacting investor sentiment positively.
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
1 month agoIceCure Medical Ltd. (NASDAQ: ICCM) announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.
IceCure Medical's compliance with Nasdaq's minimum bid price requirement signals stability and may boost investor confidence, potentially leading to increased share value and trading activity.
IceCure Medical Ltd. announced it received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic connector technology, enhancing safety in cryoablation procedures.
The patent notice enhances IceCure's competitive position, potentially leading to market exclusivity, increased revenue, and greater investor confidence in its innovative cryoablation technology.
IceCure Medical's ProSenseยฎ cryoablation for early-stage low-risk breast cancer received a favorable FDA Advisory Panel vote. FDA decision expected Q1 2025.
Positive FDA panel vote for IceCure's ProSenseยฎ could lead to market authorization, potentially increasing demand and stock value for IceCure Medical as a viable cancer treatment option.
Frequently Asked Questions About ICCM Stock
What is IceCure Medical Ltd's (ICCM) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, IceCure Medical Ltd (ICCM) has a median price target of $3.00. The highest price target is $4.60 and the lowest is $2.50.
Is ICCM stock a good investment in 2025?
According to current analyst ratings, ICCM has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ICCM stock?
Wall Street analysts predict ICCM stock could reach $3.00 in the next 12 months. This represents a 120.6% increase from the current price of $1.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IceCure Medical Ltd's business model?
IceCure Medical Ltd generates revenue through the sale of its proprietary cryoablation systems and associated disposable products. Their offerings include various systems tailored for different medical specialties, allowing them to cater to a broad market including oncology and urology.
What is the highest forecasted price for ICCM IceCure Medical Ltd?
The highest price target for ICCM is $4.60 from at , which represents a 238.2% increase from the current price of $1.36.
What is the lowest forecasted price for ICCM IceCure Medical Ltd?
The lowest price target for ICCM is $2.50 from Yi Chen at HC Wainwright & Co., which represents a 83.8% increase from the current price of $1.36.
What is the overall ICCM consensus from analysts for IceCure Medical Ltd?
The overall analyst consensus for ICCM is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are ICCM stock price projections?
Stock price projections, including those for IceCure Medical Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.